

## **THE CENTER FOR BIOTECHNOLOGY SELECTS THIRD BIOENTREPRENEUR-IN-RESIDENCE**

Pharmaceutical Executive Andreas Grill selected to evaluate emerging SBU technologies and build a new bioscience venture

**STONY BROOK, N.Y. – July 21, 2014** – The [Center for Biotechnology at Stony Brook University](#) has appointed Andreas Grill as the Center's third BioEntrepreneur-In-Residence (B-EIR). Mr. Grill brings over twenty years of experience in the pharmaceutical industry to his appointment of B-EIR, having most recently served as the Executive Director of Forest Research Institute for Forest Laboratories, Inc.

Mr. Grill will conduct due diligence to identify a technology or technologies around which he may build a company. As part of the B-EIR program, Mr. Grill will have access to the Center's business and technology development support staff. Mr. Grill's diverse and extensive experience in both business and research and development provide him with a unique perspective and advantage when it comes to launching a therapeutic-focused start-up.

The Center for Biotechnology's Advisory Board considered more than 30 candidates from around the nation for the role of B-EIR. Criteria for selection included experience developing early-stage technologies and companies, entrepreneurialism and leadership skills, and a commitment to build the company in the LI region.

"Mr. Grill brings a tremendous level of drug development expertise to the B-EIR Program and we look forward to working with him to translate one or more academic discoveries into a start-up opportunity" commented Diane Fabel, Director of Operations for the Center for Biotechnology. "Our goal throughout the process will be to accelerate the due diligence process and help de-risk the opportunity to the extent possible.

Mr. Joseph Scaduto and Mr. Reinhard Warnking are currently serving in the B-EIR role, and have made positive progress toward commercial goals.. Mr. Scaduto launched Traverse Biosciences, Inc, a biotechnology company that is focused on commercializing novel drug candidates for the treatment of inflammatory diseases and related conditions affecting humans and companion animals. He has successfully negotiated an exclusive option to license the technology from Stony Brook University and has also received venture funding through the Long Island Emerging Technologies Fund and Accelerate Long Island.

Mr. Warnking has successfully established operations for Guided Interventions, a start-up company developing a novel fractional flow reserve (FFR) guidewire technology within the Long Island High Technology Incubator in Stony Brook. The Company has secured a round of venture capital funding and is pursuing pivotal studies that could soon bring their technology to its next significant milestone.

The B-EIR program was made possible with initial contributions from the Center for Biotechnology, Stony Brook University, SUNY Research Foundation, Suffolk County Economic Development Corporation, and private donors.

Contact:

Diane Fabel

Director of Operations

[diane.fabel@stonybrook.edu](mailto:diane.fabel@stonybrook.edu)

631-632-8521

###

### **About the Center for Biotechnology at Stony Brook University**

The Center for Biotechnology is a cooperative research and development partnership between universities, private industry and New York State. It is involved in the discovery and early stage development of commercially promising technologies resulting from academic research, and the creation of strategic infrastructure that promotes the growth of the life sciences industry. The Center for Biotechnology has contributed to the development of more than a dozen approved products including ReoPro, Oracea, Cavistat, V3D Colon Virtual Colonoscopy and Exogen Bone Healing System. It has also helped launch eighteen companies.